Martin Johnson

Publications (2)16.03 Total impact

• Article: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.

  Robin Condliffe, David G Kiely, Andrew J Peacock, Paul A Corris, J Simon R Gibbs, Florenc Vrapi, Clare Das, Charlie A Elliot, Martin Johnson, Julia DeSoyza, Chantal Torpy, Kim Goldsmith, Denise Hodgkins, Rodney J Hughes, Joanna Pepke-Zaba, J Gerry Coghlan
  [show abstract] [hide abstract]
  ABSTRACT: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH) has historically had a poor prognosis, with a 1-year survival rate among patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) of 45%. However, more therapies have become available. To investigate the survival and characteristics of all patients diagnosed with CTD-PAH in the U.K. pulmonary hypertension service. National registry of all incident cases of CTD-PAH diagnosed consecutively between January 2001 and June 2006. Patients with CTD-PAH (429; 73% SSc-PAH) were diagnosed by a catheter-based approach. One- and 3-year survival rates were 78 and 47% for patients with isolated SSc-PAH. Survival was worse for those with respiratory disease-associated SSc-PAH (3-yr survival, 28%; P = 0.005) whereas survival among patients with exercise-induced SSc-PAH was superior (3-yr survival, 86%; P = < 0.001). Age, sex, mixed venous oxygen saturation, and World Health Organization functional class were independent predictors of survival in isolated SSc-PAH. Nineteen percent of patients with exercise-induced SSc-PAH and 39% of patients with isolated SSc-PAH who were in functional classes I and II had evidence of disease progression. The prevalence of diagnosed SSc-PAH is 2.93 per 1 million. The 3-year survival rate of 75% for those with pulmonary arterial hypertension associated with systemic lupus erythematosus (SLE-PAH) was significantly better than that for patients with SSc-PAH (P = 0.01). Survival of patients with SSc-PAH in the modern treatment era is better than in historical series. A significant proportion of patients with mild functional impairment or exercise-induced SSc-PAH have evidence of disease progression. Survival of patients with respiratory disease-associated pulmonary hypertension is inferior. SLE-PAH has a better prognosis than SSc-PAH.
  American Journal of Respiratory and Critical Care Medicine 10/2008; 179(2):151-7. · 11.08 Impact Factor
• Article: Commentary: Cloning humans?

  Martin Johnson
  BioEssays 02/2005; 19(8):737 - 739. · 4.95 Impact Factor